BidaskClub upgraded shares of Thermo Fisher Scientific Inc (NYSE:TMO) from a buy rating to a strong-buy rating in a research note published on Tuesday, July 11th.
A number of other equities research analysts have also recently commented on the company. Morgan Stanley increased their target price on Thermo Fisher Scientific from $186.00 to $192.00 and gave the stock an overweight rating in a research note on Friday, April 28th. Barclays PLC reissued an overweight rating and issued a $190.00 target price (up from $175.00) on shares of Thermo Fisher Scientific in a research note on Tuesday, May 9th. Deutsche Bank AG increased their target price on Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a buy rating in a research note on Friday, April 28th. Leerink Swann set a $187.00 target price on Thermo Fisher Scientific and gave the stock a buy rating in a research note on Thursday, April 27th. Finally, Cowen and Company reaffirmed an outperform rating and set a $185.00 price target (up from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Thermo Fisher Scientific has a consensus rating of Buy and an average target price of $188.56.
Shares of Thermo Fisher Scientific (NYSE:TMO) traded up 0.87% during trading on Tuesday, reaching $173.23. The company’s stock had a trading volume of 2,202,642 shares. Thermo Fisher Scientific has a one year low of $139.07 and a one year high of $182.87. The stock’s 50 day moving average is $176.78 and its 200 day moving average is $165.46. The firm has a market cap of $67.58 billion, a P/E ratio of 30.18 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the prior year, the firm posted $2.03 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific will post $9.24 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/08/11/thermo-fisher-scientific-inc-tmo-upgraded-to-strong-buy-at-bidaskclub-updated-updated-updated.html.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.45%.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Daniel P. Shine sold 4,688 shares of the stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total value of $805,773.44. Following the completion of the transaction, the insider now directly owns 29,200 shares in the company, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last three months, insiders sold 27,188 shares of company stock worth $4,702,223. 0.49% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of TMO. Proficio Capital Partners LLC increased its position in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Chicago Partners Investment Group LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Cribstone Capital Management LLC increased its position in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the period. Independent Portfolio Consultants Inc. increased its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the period. Finally, Sharkey Howes & Javer increased its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the period. 87.15% of the stock is currently owned by hedge funds and other institutional investors.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.